Advertisement

Topics

Genprex, Inc. Company Profile

02:16 EDT 22nd March 2019 | BioPortfolio

Genprex, Inc. is a clinical stage gene therapy company developing a new approach to treating cancer, based upon a novel proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.


News Articles [26 Associated News Articles listed on BioPortfolio]

Genprex, Aldevron report progress in clinical trials for lung-cancer therapy Oncoprex

Genprex will acquire more plasmid DNA vectors from Aldevron for its expanding clinical program at the MD Anderson Cancer Center

Genprex clinches deal with Aldevron to supply plasmid DNA for lung cancer-fighting therapy

The agreement paves the way for Genprex to acquire more plasmid DNA vectors for its expanding clinical program, which analyzes Oncoprex as a cancer-fighting therapy

Genprex CEO updates investors on recent $10mln capital raise, progress of cancer-fighting drug Oncoprex

Genprex (NASDAQ:GNPX) CEO Rodney Varner updates Proactive's Christine Corrado on the Austin, Texas-based biopharma's operations in the last few months, notably raising $10mln to be used toward conti...

Genprex to Present at Upcoming Investor and Industry Conferences

Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced toda...

NetworkNewsAudio Announces Audio Press Release (APR) on Genprex Inc.'s Transformative Work in Gene Therapy

New York, New York--(Newsfile Corp. - March 15, 2019) - NetworkNewsAudio announces the Audio Press Release (APR) titled "Making Profits, Saving Lives with Gene Therapy," featuring Genprex Inc. (NAS...

Genprex reaches deal with Aldevron for more plasmid DNA for expanding clinical program

Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner updates Proactive's Christine Corrado at the MicroCap Conference in New York. The clinical-stage gene therapy company has reached a deal with Aldevron, ...

Genprex to Present at the 11th Annual LD Micro Main Event

Presentation Wed., Dec. 5, 2018, at 10:30 a.m. PST Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company developing a new approach to treating cancer based upon ...

Genprex strengthens its team with new VP of clinical operations

Genprex Inc (NASDAQ:GNPX) COO Julien Pham tells Proactive Investors the clinical-stage gene therapy company has appointed Jan Stevens as its vice president of clinical operations. According to Pha...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

Genprex, Inc.

Genprex, Inc. is a clinical stage gene therapy company developing a new approach to treating cancer, based upon a novel proprietary technology platform, including Genprex’s i...

More Information about "Genprex, Inc." on BioPortfolio

We have published hundreds of Genprex, Inc. news stories on BioPortfolio along with dozens of Genprex, Inc. Clinical Trials and PubMed Articles about Genprex, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Genprex, Inc. Companies in our database. You can also find out about relevant Genprex, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...


Corporate Database Quicklinks



Searches Linking to this Company Record